Abstract
CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy, administered every 21 days (CHOP21), has been for years the standard therapy for advanced diffuse large B-cell lymphoma (DLBCL), with a long-term overall survival rate of about 40%.[1][1] Modifications of the CHOP design
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
